International Clinical Trial: Real-World Study of First-Line Treatment with Trastuzumab Biosimilar and Pertuzumab Biosimilar Combined with Chemotherapy in Patients with HER2-Positive Breast Cancer

Geneva, April 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600121627) titled 'Real-World Study of First-Line Treatment with Trastuzumab Biosimilar and Pertuzumab Biosimilar Combined with Chemotherapy in Patients with HER2-Positive Breast Cancer' on April 1.

Study Type: Observational study

Study Design: Cohort study

Primary Sponsor: The Second Qilu Hospital of Shandong University

Condition: Breast cancer

Recruitment Status: Recruiting

Phase: N/A

Date of First Enrollment: 2026-04-01

Target Sample Size: Case group:1500;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=310492

Published by HT Digital Content Services with permissi...